Clinical Trial

A Clinical Study on TILs for the Treatment of Advanced Solid Tumors

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 2, 2023 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients . The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and Interleukin-2 therapy.
Trial Details
NCT Number NCT05971576
Lead Sponsor Suzhou BlueHorse Therapeutics Co., Ltd.
Conditions Solid Tumor
Enrollment 20 participants
Start Date 2023-08
Primary Completion 2026-04 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2023-08-02